While GLP-1s dominated the obesity narrative, the next wave of innovation is focused on novel mechanisms. Arrowhead's significant fundraise for its siRNA drug highlights investor enthusiasm for approaches that offer complementary benefits, such as preserving muscle mass, signaling a new chapter in obesity treatment.

The emerging Amylin class of obesity drugs shows a consistently more favorable side effect profile than GLP-1 agonists. While weight loss efficacy may be comparable, the superior tolerability positions Amylin as a strong future competitor, either as a standalone option for sensitive patients or as a backbone for combination therapies.

The obesity drug market is moving past the "weight loss Olympics." While high efficacy is the entry ticket, new differentiators are emerging. Companies like Wave Life Sciences are focusing on muscle-sparing properties, while Structure is advancing oral GLP-1s. This indicates a maturing market where patient convenience, quality of weight loss, and long-term maintenance are becoming key value drivers.

Instead of entering the crowded obesity market, Madrigal is developing an oral GLP-1 agonist as a combination therapy. The goal is to induce modest weight loss (around 5%) which their data shows potentiates the effect of their primary MASH drug. This is a shrewd strategy to leverage a popular mechanism for a synergistic effect.

Wave Life Sciences' differentiation lies in advanced chemistry, including stereochemistry control, that results in a more durable knockdown of the target gene. This translates into a powerful competitive advantage: an infrequent dosing schedule (once or twice yearly) that dramatically improves patient convenience compared to weekly GLP-1 injections.

Wave Life Sciences' drug candidate reduced fat while increasing lean mass, even though total body weight didn't decrease. This signals a strategic shift in obesity treatment, moving beyond simple weight reduction to focus on improving body composition and mitigating muscle loss, a key side effect of GLP-1s.

Aardvark is specifically developing its oral drug for patients who have lost weight on injectable GLP-1s but want to discontinue them while preventing weight regain. This strategy taps into a massive, underserved future market of patients seeking a more convenient, long-term maintenance solution.

As the obesity market matures, the key differentiator may shift from maximum weight loss to tolerability. High discontinuation rates for GLP-1s due to GI side effects create an opportunity for drugs with slightly lower efficacy but a stellar safety profile, which could capture a large and underserved patient segment.

Rather than competing head-to-head, Aardvark's preclinical data shows combining its oral drug with a microdose of a GLP-1 injectable achieves 30% weight loss, far exceeding the GLP-1 alone. This positions their drug as a complementary therapy that enhances the existing standard of care.